West Pharmaceutical Services (WST) Stock Price, Quote & News

Company Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applicati...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 610 594 2900

Website: www.westpharma.com

Address:

530 Herman O. West Drive, Exton, United States

BillionerOfKing Jun. 1 at 5:30 PM

$WST Current Stock Price: $310.67 Contracts to trade: $310.0 WST Jun 18 2026 Call Entry: $10.10 Exit: $12.97 ROI: 28% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

semiguy May. 26 at 11:27 PM

$NSI $MPWR $MSGS $WST I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. (as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026

0 · Reply

NVDAMillionaire May. 14 at 11:22 AM

$WST Great piece that accurately captures WST's current position. So if you want to refresh your understanding of WST or learn about WST for the first time, this is essential reading. https://everyticker.com/quote/WST/analysis/three-tailwinds-converge-why-west-pharmaceutical-s-margin-expansion-is-just-beginning-nyse-wst

0 · Reply

SuperGreenToday May. 12 at 10:12 AM

$WST Share Price: $322.44 Contract Selected: Dec 18, 2026 $320 Calls Buy Zone: $22.10 – $27.30 Target Zone: $39.34 – $48.09 Potential Upside: 68% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BillionerOfKing May. 11 at 4:47 PM

$WST Current Stock Price: $323.86 Contracts to trade: $320.0 WST May 15 2026 Call Entry: $6.00 Exit: $9.23 ROI: 54% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BillionerOfKing May. 6 at 10:38 PM

$WST Current Stock Price: $312.55 Contracts to trade: $310.0 WST May 15 2026 Call Entry: $6.90 Exit: $10.28 ROI: 49% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CapitalMonk May. 6 at 5:57 PM

$WST Price: $312.73 (+0.89%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.00% RSI: 75.0 | Momentum: Strong Momentum Volume: -68.3% vs avg Volatility: 3.29% Support: $254.37 | Resistance: $320.09 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

DividendPower May. 1 at 10:36 AM

West Pharmaceutical: Multiple Growth Drivers Are A Tailwind $WST @SeekingAlpha https://seekingalpha.com/article/4897056-west-pharmaceutical-multiple-growth-drivers-are-a-tailwind

0 · Reply

PenkeInvesting Apr. 28 at 2:38 AM

Fundamental analysis of $WST (WEST PHARMACEUTICAL SERVICES INC) based on financial data and reported results. #WST #WEST

0 · Reply

OpenOutcrier Apr. 23 at 12:38 PM

$WST (+11.9% pre) West Reports First-Quarter 2026 Results https://ooc.bz/l/99766

0 · Reply

West Pharmaceutical Services Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 5:00 PM EDT - 1 day ago

West Pharmaceutical Services Slides: 46th Annual William Blair Growth Stock Conference

Jun 1, 2026, 5:21 PM EDT - 2 days ago

West Pharma names former Thermo Fisher executive Lagarde as CEO

2026-06-01T20:46:33.000Z - 2 days ago

West Pharmaceutical says Michel Lagarde to succeed Eric Green as CEO

2026-06-01T20:40:53.000Z - 2 days ago

West Pharmaceutical assumed with Outperform at Wolfe Research

Jun 1, 2026, 4:30 PM EDT - 2 days ago

West Appoints Michel Lagarde to be President and Chief Executive Officer

2026-06-01T20:13:31.000Z - 2 days ago

West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research

2026-05-29T11:02:41.000Z - 6 days ago

West Pharmaceutical price target raised to $325 from $315 at Morgan Stanley

May 20, 2026, 5:24 PM EDT - 14 days ago

West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast

May 15, 2026, 2:17 PM EDT - 19 days ago

West Pharma says operations recovering after cyberattack

2026-05-15T18:00:48.000Z - 19 days ago

West Pharmaceutical reports ‘significant progress’ in post-cyberattack recovery

May 12, 2026, 5:20 PM EDT - 22 days ago

West Pharmaceutical Services Transcript: Bank of America Global Healthcare Conference 2026

May 4, 2026, 9:30 AM EDT - 4 weeks ago

West Pharmaceutical Services Transcript: AGM 2026

Apr 28, 2026, 6:00 AM EDT - 5 weeks ago

West to Participate in Upcoming Investor Conferences

2026-04-27T12:37:25.000Z - 5 weeks ago

West Pharmaceutical price target raised to $315 from $285 at Morgan Stanley

2026-04-27T10:09:46.000Z - 5 weeks ago

West Pharmaceutical price target raised to $310 from $275 at Barclays

2026-04-24T14:29:57.000Z - 5 weeks ago

West Pharmaceutical price target raised to $400 from $375 at Citi

2026-04-24T12:20:43.000Z - 5 weeks ago

West Pharmaceutical price target raised to $390 from $320 at Evercore ISI

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

West Pharmaceutical Services Earnings Call Transcript: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

West Pharmaceutical Services Slides: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

West Pharmaceutical Services Earnings release: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

West Pharmaceutical Services Quarterly report: Q1 2026

Apr 23, 2026, 7:03 AM EDT - 6 weeks ago

West Pharma lifts 2026 profit forecast on strong demand for medical equipment

Apr 23, 2026, 6:00 AM EDT - 6 weeks ago

West Reports First-Quarter 2026 Results

2026-04-14T10:45:33.000Z - 7 weeks ago

West Pharmaceutical price target raised to $275 from $265 at Barclays

Apr 9, 2026, 6:00 AM EDT - 2 months ago

West to Host First-Quarter 2026 Conference Call

2026-03-31T15:50:47.000Z - 2 months ago

West Pharmaceutical expands Damastown, Dublin facility

Mar 31, 2026, 11:46 AM EDT - 2 months ago

West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity

Mar 18, 2026, 1:30 PM EDT - 2 months ago

West Pharmaceutical Services Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 12, 2026, 8:00 AM EDT - 3 months ago

West Pharmaceutical Services Proxy statement: Proxy Filing

Mar 12, 2026, 8:00 AM EDT - 3 months ago

West Pharmaceutical Services Proxy statement: Proxy Filing

Mar 10, 2026, 9:00 AM EDT - 3 months ago

West Pharmaceutical Services Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 5:07 PM EDT - 3 months ago

West Pharma CEO Eric Green to retire after 11 years at the helm

2026-03-09T20:37:20.000Z - 3 months ago

West Pharmaceutical says CEO Eric Green to retire

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc.

Feb 17, 2026, 4:00 PM EST - 3 months ago

West Announces Quarterly Dividend and Share Repurchase Program

2026-02-13T16:50:39.000Z - 3 months ago

West Pharmaceutical price target lowered to $300 from $370 at BofA

Feb 12, 2026, 8:00 AM EST - 4 months ago

West Pharmaceutical Services Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

West Pharmaceutical Services Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

West Pharmaceutical Services Earnings release: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

West Pharmaceutical Services Slides: Q4 2025

Feb 12, 2026, 6:58 AM EST - 4 months ago

West Pharma forecasts 2026 profit above estimates on strong demand for drug components

Feb 12, 2026, 6:00 AM EST - 4 months ago

West Reports Fourth-Quarter and Full-Year 2025 Results

Feb 5, 2026, 11:00 AM EST - 4 months ago

West Pharmaceutical Services Transcript: Status update

Jan 29, 2026, 6:00 AM EST - 4 months ago

West to Host Fourth-Quarter and Full-Year 2025 Conference Call

Jan 26, 2026, 10:00 AM EST - 4 months ago

Time To Buy The Dip In West Pharmaceutical Stock?

Jan 20, 2026, 6:00 AM EST - 4 months ago

West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

Jan 14, 2026, 12:00 PM EST - 5 months ago

West Pharmaceutical Services Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 5 months ago

West Pharmaceutical Services Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:00 AM EST - 5 months ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

ABBV

Jan 12, 2026, 6:00 AM EST - 5 months ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

ABBV

Dec 12, 2025, 6:00 AM EST - 6 months ago

West to Participate in Upcoming Investor Conference

Dec 10, 2025, 6:00 AM EST - 6 months ago

West Declares Quarterly Dividend

Dec 2, 2025, 2:30 PM EST - 6 months ago

West Pharmaceutical Services Transcript: Citi Annual Global Healthcare Conference 2025

Nov 20, 2025, 12:00 PM EST - 6 months ago

West Pharmaceutical Services Transcript: Stephens Annual Investment Conference

Nov 18, 2025, 5:00 AM EST - 7 months ago

West Pharmaceutical Services Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:24 AM EST - 7 months ago

These stocks have been hit hard in 2025 but could surge by as much as 57% from here

ADBE ALGN BLDR CARR CMG CPRT CRM

Nov 11, 2025, 9:30 AM EST - 7 months ago

West Pharmaceutical Services Transcript: UBS Global Healthcare Conference 2025

Oct 27, 2025, 6:00 AM EDT - 7 months ago

West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery

Oct 23, 2025, 8:00 AM EDT - 8 months ago

West Pharmaceutical Services Earnings Call Transcript: Q3 2025

Oct 23, 2025, 8:00 AM EDT - 8 months ago

West Pharmaceutical Services Quarterly report: Q3 2025

Oct 23, 2025, 8:00 AM EDT - 8 months ago

West Pharmaceutical Services Earnings release: Q3 2025

Oct 23, 2025, 8:00 AM EDT - 8 months ago

West Pharmaceutical Services Slides: Q3 2025

Oct 23, 2025, 6:52 AM EDT - 8 months ago

West Pharma boosts annual profit forecast on strong demand for its drug components

Oct 23, 2025, 6:00 AM EDT - 8 months ago

West Reports Third-Quarter 2025 Results

Oct 9, 2025, 6:00 AM EDT - 8 months ago

West to Host Third-Quarter 2025 Conference Call

Sep 24, 2025, 11:05 AM EDT - 9 months ago

West Pharmaceutical Services Transcript: Bank of America Global Healthcare Conference 2025

Sep 3, 2025, 3:00 PM EDT - 9 months ago

West Pharmaceutical Services Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 21, 2025, 6:00 AM EDT - 10 months ago

West to Participate in Upcoming Investor Conferences in September 2025

Jul 24, 2025, 8:02 AM EDT - 11 months ago

West Pharma raises annual profit forecast on strong demand for its drug components

Jul 24, 2025, 8:00 AM EDT - 11 months ago

West Pharmaceutical Services Earnings Call Transcript: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 11 months ago

West Pharmaceutical Services Quarterly report: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 11 months ago

West Pharmaceutical Services Earnings release: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 11 months ago

West Pharmaceutical Services Slides: Q2 2025

Jul 24, 2025, 6:00 AM EDT - 11 months ago

West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance

Jul 21, 2025, 6:00 AM EDT - 11 months ago

West Welcomes Robert McMahon as Incoming Chief Financial Officer

Jul 8, 2025, 6:00 AM EDT - 11 months ago

West to Host Second-Quarter 2025 Conference Call

Jul 7, 2025, 2:23 AM EDT - 11 months ago

WST Shareholders Have the Right to Lead the West Pharmaceutical Services, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - WST

BillionerOfKing Jun. 1 at 5:30 PM

0 · Reply

semiguy May. 26 at 11:27 PM

0 · Reply

NVDAMillionaire May. 14 at 11:22 AM

0 · Reply

SuperGreenToday May. 12 at 10:12 AM

0 · Reply

BillionerOfKing May. 11 at 4:47 PM

0 · Reply

BillionerOfKing May. 6 at 10:38 PM

0 · Reply

CapitalMonk May. 6 at 5:57 PM

0 · Reply

DividendPower May. 1 at 10:36 AM

West Pharmaceutical: Multiple Growth Drivers Are A Tailwind $WST @SeekingAlpha https://seekingalpha.com/article/4897056-west-pharmaceutical-multiple-growth-drivers-are-a-tailwind

0 · Reply

PenkeInvesting Apr. 28 at 2:38 AM

Fundamental analysis of $WST (WEST PHARMACEUTICAL SERVICES INC) based on financial data and reported results. #WST #WEST

0 · Reply

OpenOutcrier Apr. 23 at 12:38 PM

$WST (+11.9% pre) West Reports First-Quarter 2026 Results https://ooc.bz/l/99766

0 · Reply

StocktwitsEarnings Apr. 23 at 11:16 AM

$WST Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.93 up 55.65% YoY • Reported revenue of $844.9M up 21.05% YoY • West Pharmaceutical Services increased its full-year 2026 net sales guidance to a range of $3.295 billion to $3.350 billion and adjusted-diluted EPS guidance to $8.40 to $8.75.

0 · Reply

Estimize Apr. 23 at 10:00 AM

$WST reported - EPS and - revenue for Q1. http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_content=WST&utm_medium=act

0 · Reply

IN0V8 Apr. 15 at 4:35 PM

$WST Barclays raises PT to $275 from $265

0 · Reply

ZacksResearch Mar. 11 at 6:26 PM

GLP-1 demand tailwind for $WST — but there’s a catch investors shouldn’t ignore. Growth is being fueled by high-value components, rising GLP-1 drug demand, and Annex 1 conversions. But risks are still on the table with generics destocking and European capacity constraints creating potential pressure. ⚖️ See the full opportunity and risk breakdown 👉 https://www.zacks.com/stock/news/2882595/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-right-now?cid=sm-stocktwits-2-2882595-teaser-37054&ADID=SYND_STOCKTWITS_TWEET_2_2882595_TEASER_37054

0 · Reply

ZacksResearch Mar. 11 at 5:26 PM

$WST down 11.3% in 6 months — growth driven by strong demand 📈 ✅ Strong demand for high-value products & GLP-1 therapies 💰 Anticipated 11.8% earnings growth over the next 5 years ⚠️ Operational challenges and destocking in European facilities may impact short-term gains See what makes this Zacks Rank #2 stock a potential buy 👉 https://www.zacks.com/stock/news/2882595/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-right-now?cid=sm-stocktwits-2-2882595-body-37055&ADID=SYND_STOCKTWITS_TWEET_2_2882595_BODY_37055

0 · Reply

Estimize Feb. 23 at 12:00 PM

Wall St is expecting 1.68 EPS for $WST Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_cont

0 · Reply

deankell Feb. 18 at 1:37 AM

$WST West Pharmaceutical (WST) declares $0.22/share quarterly dividend, in line with previous. Forward yield 0.36% Payable May 6; for shareholders of record April 29; ex-div April 29.

0 · Reply

deankell Feb. 18 at 1:28 AM

$WST 17 Feb 2026 05:19:12 PM | Seeking Alpha West Pharmaceutical Services (WST) said its board has authorized an up to $1B share repurchase program. The company exhausted a prior buyback that had an expiration date of Dec. 31.

0 · Reply

d_risk Feb. 17 at 10:04 PM

$WST - West Pharmaceutical Services Inc - 10K - Updated Risk Factors WST’s 2026 10-K sharpens macro and operational risk: deeper focus on recession and market volatility, tariffs and banking fragility, capacity and supply-chain fragility (single-source and climate/pandemic disruptions), new credit and customer concentration risks, added product liability and GLP-1 displacement threats, climate and PFAS exposure, tighter anti-bribery and reimbursement headwinds, deal and Daikyo licensing execution risk, talent and innovation dependence, dividends not assured, and a new warning on internal controls and potential stock hit. #PharmaceuticalManufacturing #MarketVolatility #SupplyChainRisk #RegulatoryCompliance #ClimateExposure 🟢 Added 🟠 Removed https://d-risk.ai/WST/10-K/2026-02-17

0 · Reply

Market Cap	22.05B
Revenue (ttm)	3.07B
Net Income (ttm)	493.70M
EPS (ttm)	N/A
PE Ratio	39.69
Forward PE	36.79
Profit Margin	16.06%
Debt to Equity Ratio	0.07

Volume	636,100
Avg Vol	883,804
Day's Range	N/A - N/A
Shares Out	70.65M
Stochastic %K	94%
Beta	1.18
Analysts	Strong Sell
Price Target	$351.38